The Avillion Effect

Our unique partnership model and industry expertise turn R&D challenges into breakthrough opportunities with 100% success over 12 years.
Get in Touch

Operational Excellence

Leveraging our expertise, Avillion accelerates clinical trials through faster study starts, quicker site activations, and rapid enrolment. We achieve this without sacrificing quality, offering significant time and cost efficiencies that translate to tangible economic benefits for our partners. This approach not only streamlines the development process but also enhances the overall quality of data collected, positioning our partners for success in regulatory submissions and market entry.

Tailored Collaboration Models

With a deep commitment to clinical development expertise, Avillion offers bespoke financing arrangements and operates a flexible, collaborative business model. We assums all financial risks, funding the agreed development programmes to enable partners to manage their P&L effectively. We adapt roles and responsibilities to meet each co-development partner's unique needs, ensuring optimal alignment and mutual success.

Strategic Resource Optimisation

Avillion's innovative approach enables pharmaceutical companies to optimise their R&D resources effectively. We provide a solution for continuing asset development that might otherwise stall due to financial or resource constraints, allowing our partners to maximise their portfolio potential without compromising ongoing projects.

Quality-Centric Approach

We maintain an unwavering focus on high-quality outcomes through robust oversight and strong relationships with trial investigators. Our approach includes direct site support, intensive audits, and effective management of patient care and adverse events, ensuring data integrity and regulatory compliance.

Unparalleled Expertise

Avillion’s team, with over 235 years of combined experience, stands at the forefront of clinical development excellence. Our professionals average more than 22 years of pharmaceutical industry experience, bringing deep expertise to every project.

This diverse group includes medical doctors, biostatisticians, quality assurance professionals, regulatory experts, and seasoned project managers. Strategically located across North America, Europe, and Asia-Pacific, our global team ensures 24/7 support and local insights.

Each team member is carefully selected for their expertise and dedication to advancing clinical development. Their collective involvement in over 90 successful drug approvals demonstrates our ability to navigate complex regulatory landscapes and deliver results.

The Avillion Effect

Our approach to clinical trials embodies the Avillion Effect – a unique combination of expertise, strategy, and hands-on management that consistently outperforms industry standards.

Key components of the Avillion Effect include:

  • Accelerated recruitment: Our Phase 3 oncology study for Pfizer recruited 13 months faster than expected.
  • Expedited approvals: We delivered successful approval 1 year ahead of expectations for a key partner.
  • Quality data: In our global asthma programme, we achieved a remarkably low 6% overall discontinuation rate across 4,000+ patients.

This effect extends to daily trial management, fostering a unified team approach that enhances execution speed, study setup optimisation, and accelerated patient enrolment. The result is high-quality data output and condensed timelines, crucial for streamlined execution of studies.

Quality-Driven Timely Results

At Avillion, quality isn’t just a goal; it’s the foundation of our operational excellence. Our model integrates strategic partnerships with an intensive, bespoke audit programme, overseen by our Head of Quality Assurance.

This programme includes:

  • Comprehensive audits of CRO partners, third-party suppliers, and investigator sites
  • Robust oversight and strong relationships with trial investigators
  • Effective management of patient care and adverse events

Our unwavering focus on quality, paired with our strategic and operational expertise, consistently results in significant time savings compared to traditional models. This is evidenced by our track record:

  • 100% of Phase II/III trials completed on time, achieving all primary and key secondary endpoints
  • Average of 110 days from LPLV to CSR, demonstrating our commitment to rapid, high-quality data delivery

The Avillion Effect, combined with our quality-centric approach, ensures we deliver reliable, timely results that accelerate the path to regulatory approval and market entry.

Accelerated Development

Our seasoned drug development team, with over 235 years of combined experience, optimises clinical trials through expert oversight. We leverage best practices to accelerate site activation, patient enrolment, and study completion without compromising quality. Our track record includes completing 100% of Phase II/III trials on time, achieving all primary and key secondary endpoints.

Flexible Collaboration

Avillion offers tailored engagement models to suit our partners’ needs. Whether it’s our classic P&L relief model, in-licensing of assets, or collaborative work alongside biotech/pharma companies, we adapt nimbly to operate as a seamless extension of our partner’s team. Our global reach spans 31 countries, enabling efficient execution of worldwide clinical programmes.

Quality & Compliance

Our unwavering focus on quality and oversight is a core Avillion advantage. We work closely with trial investigators, conducting site initiation visits, monitoring patient care and adverse events, and implementing rigorous audit programmes. This approach has resulted in exceptional data quality, with only a 6% overall discontinuation rate across 4,000+ patients in our global asthma programme.

Elevate Your R&D Potential with Avillion

Discover the Avillion difference. Let's innovate together.
Get In Touch